Exclusive Distribution Agreement Signed Between Hempacco and CBDAY in India and Thailand

Business by 2FIRSTS.ai
Dec.08.2023
Exclusive Distribution Agreement Signed Between Hempacco and CBDAY in India and Thailand
Hempacco Co, Inc. (HPCO) has signed an exclusive distribution agreement with CBDAY Global Private Limited to sell cannabis products in India and Thailand.

According to a report by Benzinga on December 6th, the cannabis tobacco company Hempacco Co, Inc. (code: HPCO) has announced that it has signed an exclusive distribution agreement with CBDAY Global Private Limited (a company that imports, exports, distributes, and sells hemp-based products in India and Asia).

 

According to the agreement, CBDAY will have exclusive sales rights for Hempacco's cannabis and CBD products in India and Thailand. The initial offerings will include Cheech & Chong and Rick Ross' marijuana products, which will be available for purchase on CBDAY's flagship website. These premium cannabis products will be distributed throughout the Asia region via CBDAY's extensive online and offline sales channels. This expansion reflects their commitment to providing high-quality hemp and CBD products to consumers worldwide.

 

The Indian market holds immense potential for cannabis-based products due to the country's long-standing use of the hemp plant for various purposes. In certain regions of India, particularly the state of Uttar Pradesh, some tribal communities may engage in the use of marijuana, and related laws might have a degree of leniency towards them.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Observation | U.S. E-cigarette Regulation Enters Normalized Phase as Federal and State Authorities Tighten Compliance Frameworks
2Firsts Observation | U.S. E-cigarette Regulation Enters Normalized Phase as Federal and State Authorities Tighten Compliance Frameworks
In just two months, U.S. authorities seized over 7 million illegal e-cigarettes. 2Firsts’ analysis reveals a shift toward institutionalized regulation, with federal and state agencies intensifying enforcement — signaling a major reset in the world’s largest and most influential vaping market.
Oct.28
Texas e-cigarette shop owner arrested for allegedly hiding an unfinished tunnel inside his shop, possibly linked to international smuggling
Texas e-cigarette shop owner arrested for allegedly hiding an unfinished tunnel inside his shop, possibly linked to international smuggling
During a raid by federal and local law enforcement officers at an e-cigarette shop in Laredo, Texas, a 25-foot-deep tunnel, possibly linked to a transnational criminal organization, was discovered. The shop's owner, Gilberto Pena, was arrested for possession of controlled substances. Cocaine and marijuana were also seized during the raid. A total of 22 e-cigarette shops were inspected in Laredo, resulting in one arrest. The shop in question remains open, but the tunnel will be removed.
Sep.24 by 2FIRSTS.ai
Dutch Ministry of Finance reports: Dutch tobacco tax revenue stagnates, mainly due to cross-border consumption shift
Dutch Ministry of Finance reports: Dutch tobacco tax revenue stagnates, mainly due to cross-border consumption shift
A report released by the Dutch Ministry of Finance indicates that tobacco tax increases have failed to boost fiscal revenue. The previously projected €7 million in revenue from a 5 cent per pack tax increase has now fallen to zero, primarily due to cross-border cigarette purchases. The current excise tax on cigarettes is €7.81 per pack, with no further increases planned. Tobacco tax revenue is projected to reach €2.5 billion in both 2025 and 2026.
Sep.24 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Chelyabinsk Doctor Warns of E-Cigarette Dangers After Explosion Incident in Russia, No Injuries Reported
Chelyabinsk Doctor Warns of E-Cigarette Dangers After Explosion Incident in Russia, No Injuries Reported
Doctor Anton Ryzhiy warns of the dangers of e-cigarettes after explosion in Chelyabinsk, Russia, highlighting concerns for youth health.
Sep.17 by 2FIRSTS.ai
FDA CTP Acting Director  Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
FDA CTP Acting Director Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
At the FDLI Tobacco and Nicotine Policy Conference, FDA CTP Acting Director Bret Koplow spoke in favor of promoting tobacco harm reduction to reduce smoking. He backed a legal marketplace for authorized reduced-risk products, potential expansion of flavored e-cigs, and faster FDA reviews to ensure a strong, regulated market.
Oct.29 by 2FIRSTS.ai